<p>AWM Investment Company Inc. 在第二季度购买了 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免费报告）的新头寸，根据该公司在最近向 SEC 提交的 13F 表格。该公司购买了 470,000 股生物制药公司的股票，价值约为 2,670,000 美元。AWM Investment Company Inc. 在最近一个季度末持有约 0.92% 的 Abeona Therapeutics。</p>
<p>获取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
<p>其他几家对冲基金最近也调整了对该公司的持股。Creative Planning 在第二季度将其在 Abeona Therapeutics 的股份增加了 43.0%。Creative Planning 目前拥有 14,310 股生物制药公司的股票，价值 81,000 美元，此前在上个季度又购买了 4,305 股。Ameritas Investment Partners Inc. 在第二季度购买了 Abeona Therapeutics 的新头寸，价值约为 25,000 美元。Legal &amp; General Group Plc 在第二季度购买了 Abeona Therapeutics 的新股份，价值约为 27,000 美元。OMERS ADMINISTRATION Corp 在第一季度将其在 Abeona Therapeutics 的股份增加了 11.0%。OMERS ADMINISTRATION Corp 目前拥有 72,200 股生物制药公司的股票，价值 344,000 美元，此前在该期间又收购了 7,155 股。最后，Riverwater Partners LLC 在第二季度购买了 Abeona Therapeutics 的新头寸，价值约为 62,000 美元。对冲基金和其他机构投资者持有该公司 80.56% 的股票。</p>
<h2>分析师升级和降级</h2>
<p>ABEO 已成为几份研究报告的主题。HC Wainwright 在 10 月 13 日的报告中重申了对 Abeona Therapeutics 的 &#34;买入&#34; 评级，并给出了 20.00 美元的目标价。Weiss Ratings 在 10 月 24 日的研究报告中将 Abeona Therapeutics 的评级从 &#34;持有（c-）&#34; 降级为 &#34;卖出（d+）&#34;。Oppenheimer 在 8 月 15 日的报告中将 Abeona Therapeutics 的目标价从 19.00 美元上调至 20.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。最后，Wall Street Zen 在 11 月 15 日的研究报告中将 Abeona Therapeutics 的评级从 &#34;持有&#34; 降级为 &#34;卖出&#34;。四位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Abeona Therapeutics 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 20.00 美元。</p>
<p><strong>查看我们对 ABEO 的最新股票分析</strong></p>
<h2>Abeona Therapeutics 股价下跌 2.9%</h2>
<p>ABEO 股票在周五开盘价为 5.36 美元。该公司的债务与股本比率为 0.06，流动比率为 9.74，速动比率为 9.53。该公司的市值为 2.9046 亿美元，市盈率为 4.36，贝塔值为 1.12。Abeona Therapeutics Inc. 的一年低点为 3.93 美元，一年高点为 7.54 美元。该公司的 50 日移动平均价格为 4.98 美元，200 日移动平均价格为 5.81 美元。</p>
<p>Abeona Therapeutics（NASDAQ:ABEO - 获取免费报告）最近于 11 月 12 日发布了其财报。这家生物制药公司报告本季度每股收益为（0.10）美元，超出市场共识预期的（0.27）美元，超出幅度为 0.17 美元。整体来看，股票分析师预测 Abeona Therapeutics Inc. 本年度每股收益将为 -1.16 美元。</p>
<h2>内部买卖</h2>
<p>在相关消息中，董事 Mark Alvino 于 11 月 13 日星期四出售了 15,000 股 Abeona Therapeutics 股票。股票以平均价格 4.74 美元出售，总交易额为 71,100.00 美元。交易后，该董事在公司持有 62,252 股，价值约为 295,074.48 美元。此次交易使其持股减少了 19.42%。该交易已在向证券交易委员会的备案中披露，您可以通过此链接访问。此外，首席执行官 Vishwas Seshadri 于 9 月 30 日星期二出售了 25,000 股公司的股票。该股票以平均价格 5.24 美元出售，总交易额为 131,000.00 美元。交易完成后，首席执行官直接持有 1,190,067 股公司的股票，价值 6,235,951.08 美元。这代表其持股减少了 2.06%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了价值 410,271 美元的 78,612 股公司股票。公司内部人士持有该公司 6.90% 的股票。</p>
<h2>关于 Abeona Therapeutics</h2>
<p>（免费报告）</p>
<p>Abeona Therapeutics Inc. 是一家临床阶段的生物制药公司，专注于开发和提供针对严重和危及生命的罕见疾病的基因治疗产品。该公司的主要项目包括 EB-101（基因修正的皮肤移植）用于隐性营养不良性表皮松解症（RDEB）；ABO-102，是针对 A 型 Sanfilippo 综合症的 AAV 基因治疗；以及 ABO-101，是针对 B 型 Sanfilippo 综合症的腺病毒相关病毒（AAV）基因治疗。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票比 Abeona Therapeutics 更好</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>Synopsys 看到乐观转变，因为 Ansys 整合推动增长</li>
<li>投资于高市盈率成长股</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>最佳股息贵族名单：通过贵族指数积累财富</li>
<li>为什么 Zscaler 股票在 30% 的抛售后可能准备反弹</li>
</ul>
<p><strong>想看看其他对冲基金持有 ABEO 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免费报告）的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Abeona Therapeutics 吗？</h2>
<p>在考虑 Abeona Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Abeona Therapeutics 并不在名单上。</p>
<p>虽然 Abeona Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Abeona治疗

<p>AWM Investment Company Inc. 收购了 470,000 股 Abeona Therapeutics Inc. 的股份，价值 2,670,000 美元，持有该公司 0.92% 的股份。分析师的评级不一，普遍目标价为 20.00 美元。Abeona 的股票开盘价为 5.36 美元，市值为 2.9046 亿美元。内部人士最近出售了价值 410,271 美元的股份</p>

<p>AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company's stock, valued at approximately $2,670,000. AWM Investment Company Inc. owned approximately 0.92% of Abeona Therapeutics at the end of the most recent quarter.</p>
<div class="lb-trans"><p>AWM Investment Company Inc. 在第二季度购买了 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免费报告）的新头寸，根据该公司在最近向 SEC 提交的 13F 表格。该公司购买了 470,000 股生物制药公司的股票，价值约为 2,670,000 美元。AWM Investment Company Inc. 在最近一个季度末持有约 0.92% 的 Abeona Therapeutics。</p>
</div><p>Get <strong>Abeona Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
</div><p>Several other hedge funds have also recently modified their holdings of the business. Creative Planning boosted its position in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in Abeona Therapeutics during the 2nd quarter valued at about $25,000. Legal &amp; General Group Plc purchased a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at about $27,000. OMERS ADMINISTRATION Corp grew its stake in shares of Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after acquiring an additional 7,155 shares during the period. Finally, Riverwater Partners LLC purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 80.56% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对该公司的持股。Creative Planning 在第二季度将其在 Abeona Therapeutics 的股份增加了 43.0%。Creative Planning 目前拥有 14,310 股生物制药公司的股票，价值 81,000 美元，此前在上个季度又购买了 4,305 股。Ameritas Investment Partners Inc. 在第二季度购买了 Abeona Therapeutics 的新头寸，价值约为 25,000 美元。Legal &amp; General Group Plc 在第二季度购买了 Abeona Therapeutics 的新股份，价值约为 27,000 美元。OMERS ADMINISTRATION Corp 在第一季度将其在 Abeona Therapeutics 的股份增加了 11.0%。OMERS ADMINISTRATION Corp 目前拥有 72,200 股生物制药公司的股票，价值 344,000 美元，此前在该期间又收购了 7,155 股。最后，Riverwater Partners LLC 在第二季度购买了 Abeona Therapeutics 的新头寸，价值约为 62,000 美元。对冲基金和其他机构投资者持有该公司 80.56% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>ABEO has been the topic of several research reports. HC Wainwright restated a &#34;buy&#34; rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings downgraded Abeona Therapeutics from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Friday, October 24th. Oppenheimer lifted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, August 15th. Finally, Wall Street Zen cut Abeona Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $20.00.</p>
<div class="lb-trans"><p>ABEO 已成为几份研究报告的主题。HC Wainwright 在 10 月 13 日的报告中重申了对 Abeona Therapeutics 的 &#34;买入&#34; 评级，并给出了 20.00 美元的目标价。Weiss Ratings 在 10 月 24 日的研究报告中将 Abeona Therapeutics 的评级从 &#34;持有（c-）&#34; 降级为 &#34;卖出（d+）&#34;。Oppenheimer 在 8 月 15 日的报告中将 Abeona Therapeutics 的目标价从 19.00 美元上调至 20.00 美元，并给予该股票 &#34;跑赢大盘&#34; 的评级。最后，Wall Street Zen 在 11 月 15 日的研究报告中将 Abeona Therapeutics 的评级从 &#34;持有&#34; 降级为 &#34;卖出&#34;。四位研究分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Abeona Therapeutics 目前的平均评级为 &#34;适度买入&#34;，共识目标价为 20.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on ABEO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ABEO 的最新股票分析</strong></p>
</div><h2>Abeona Therapeutics Trading Down 2.9%</h2>
<div class="lb-trans"><h2>Abeona Therapeutics 股价下跌 2.9%</h2>
</div><p>Shares of ABEO stock opened at $5.36 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The company has a market cap of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a fifty day moving average price of $4.98 and a 200-day moving average price of $5.81.</p>
<div class="lb-trans"><p>ABEO 股票在周五开盘价为 5.36 美元。该公司的债务与股本比率为 0.06，流动比率为 9.74，速动比率为 9.53。该公司的市值为 2.9046 亿美元，市盈率为 4.36，贝塔值为 1.12。Abeona Therapeutics Inc. 的一年低点为 3.93 美元，一年高点为 7.54 美元。该公司的 50 日移动平均价格为 4.98 美元，200 日移动平均价格为 5.81 美元。</p>
</div><p>Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>Abeona Therapeutics（NASDAQ:ABEO - 获取免费报告）最近于 11 月 12 日发布了其财报。这家生物制药公司报告本季度每股收益为（0.10）美元，超出市场共识预期的（0.27）美元，超出幅度为 0.17 美元。整体来看，股票分析师预测 Abeona Therapeutics Inc. 本年度每股收益将为 -1.16 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $4.74, for a total transaction of $71,100.00. Following the transaction, the director owned 62,252 shares in the company, valued at approximately $295,074.48. The trade was a 19.42% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total transaction of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares of the company's stock, valued at $6,235,951.08. This represents a 2.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 78,612 shares of company stock valued at $410,271 in the last 90 days. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Mark Alvino 于 11 月 13 日星期四出售了 15,000 股 Abeona Therapeutics 股票。股票以平均价格 4.74 美元出售，总交易额为 71,100.00 美元。交易后，该董事在公司持有 62,252 股，价值约为 295,074.48 美元。此次交易使其持股减少了 19.42%。该交易已在向证券交易委员会的备案中披露，您可以通过此链接访问。此外，首席执行官 Vishwas Seshadri 于 9 月 30 日星期二出售了 25,000 股公司的股票。该股票以平均价格 5.24 美元出售，总交易额为 131,000.00 美元。交易完成后，首席执行官直接持有 1,190,067 股公司的股票，价值 6,235,951.08 美元。这代表其持股减少了 2.06%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了价值 410,271 美元的 78,612 股公司股票。公司内部人士持有该公司 6.90% 的股票。</p>
</div><h2>About Abeona Therapeutics</h2>
<div class="lb-trans"><h2>关于 Abeona Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.</p>
<div class="lb-trans"><p>Abeona Therapeutics Inc. 是一家临床阶段的生物制药公司，专注于开发和提供针对严重和危及生命的罕见疾病的基因治疗产品。该公司的主要项目包括 EB-101（基因修正的皮肤移植）用于隐性营养不良性表皮松解症（RDEB）；ABO-102，是针对 A 型 Sanfilippo 综合症的 AAV 基因治疗；以及 ABO-101，是针对 B 型 Sanfilippo 综合症的腺病毒相关病毒（AAV）基因治疗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Abeona Therapeutics</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>Investing in the High PE Growth Stocks</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Abeona Therapeutics 更好</li>
<li>股票交易术语 - 每个投资者需要了解的股票术语</li>
<li>Synopsys 看到乐观转变，因为 Ansys 整合推动增长</li>
<li>投资于高市盈率成长股</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>最佳股息贵族名单：通过贵族指数积累财富</li>
<li>为什么 Zscaler 股票在 30% 的抛售后可能准备反弹</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABEO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 ABEO 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免费报告）的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ABEO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abeona Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Abeona Therapeutics 吗？</h2>
</div><p>Before you consider Abeona Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Abeona Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Abeona Therapeutics 并不在名单上。</p>
</div><p>While Abeona Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Abeona Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AWM 投资公司收购 Abeona 治疗公司新股份 $ABEO